Optimization of the solubility of HIV-1-neutralizing antibody 10E8 through somatic variation and structure-based design

Journal of Virology

Volumn 90, Issue 13, 2016, Pages 5899-5914

  Kwon, Young D ^a   Georgiev, Ivelin S ^a   Ofek, Gilad ^a   Zhang, Baoshan ^a   Asokan, Mangaiarkarasi ^a   Bailer, Robert T ^a   Bao, Amy ^a   Caruso, William ^a   Chen, Xuejun ^a   Choe, Misook ^a   Druz, Aliaksandr ^a   Ko, Sung Youl ^a   Louder, Mark K ^a   McKee, Krisha ^a   O'Dell, Sijy ^a   Pegu, Amarendra ^a   Rudicell, Rebecca S ^a   Shi, Wei ^a   Wang, Keyun ^a   Yang, Yongping ^a   Alger, Mandy ^a   Bender, Michael F ^a   Carlton, Kevin ^a   Cooper, Jonathan W ^a   Blinn, Julie ^b   Eudailey, Joshua ^b   Lloyd, Krissey ^b   Parks, Robert ^b   Alam, S Munir ^b   Haynes, Barton F ^b   Padte, Neal N ^c   Yu, Jian ^c   Ho, David D ^c   Huang, Jinghe ^a   Connors, Mark ^a   Schwartz, Richard M ^a   Mascola, John R ^a   Kwong, Peter D ^a   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY 10E8; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; DISULFIDE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY STRUCTURE; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DISULFIDE BOND; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SOLUBILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOMERIZATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RHESUS MONKEY; SIZE EXCLUSION CHROMATOGRAPHY; VIRUS NEUTRALIZATION; ANIMAL; CHEMICAL ANALYSIS; CHEMICAL PHENOMENA; CHEMISTRY; GENETICS; HALF LIFE TIME; HIGH THROUGHPUT SEQUENCING; HUMAN; IMMUNOLOGY; METABOLISM; MOLECULAR MODEL; SOLUBILITY; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTIBODIES, NEUTRALIZING; CHEMISTRY TECHNIQUES, ANALYTICAL; CRYSTALLOGRAPHY, X-RAY; DISULFIDES; HALF-LIFE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV ANTIBODIES; HIV-1; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MACACA MULATTA; MODELS, MOLECULAR; SOLUBILITY;

EID: 84975311484     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03246-15     Document Type: Article

References (44)

1. Corti D, Langedijk JPM, Hinz A, Seaman MS, Vanzetta F, Fernandez-Rodriguez BM, Silacci C, Pinna D, Jarrossay D, Balla-Jhagjhoorsingh S, Willems B, Zekveld MJ, Dreja H, O'Sullivan E, Pade C, Orkin C, Jeffs SA, Montefiori DC, Davis D, Weissenhorn W, McKnight A, Heeney JL, Sallusto F, Sattentau QJ, Weiss RA, Lanzavecchia A. 2010. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 5:e8805. http://dx.doi.org/10.1371/journal.pone.0008805.
2. Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, DeKosky BJ, Ernandes MJ, Georgiev IS, Kim HJ, Pancera M, Staupe RP, Altae-Tran HR, Bailer RT, Crooks ET, Cupo A, Druz A, Garrett NJ, Hoi KH, Kong R, Louder MK, Longo NS, McKee K, Nonyane M, O'Dell S, Roark RS, Rudicell RS, Schmidt SD, Sheward DJ, Soto C, Wibmer CK, Yang YP, Zhang ZH, Mullikin JC, Binley JM, Sanders RW, Wilson IA, Moore JP, Ward AB, Georgiou G, Williamson C, Karim SSA, Morris L, Kwong PD, Shapiro L, Mascola JR. 2014. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509:55-62. http://dx.doi.org/10.1038/nature13036.
3. Falkowska E, Le KM, Ramos A, Doores KJ, Lee JH, Blattner C, Ramirez A, Derking R, MJ van Gils Liang CH, Mcbride R, von Bredow B, Shivatare SS, Wu CY, Chan-Hui PY, Liu Y, Feizi T, Zwick MB, Koff WC, Seaman MS, Swiderek K, Moore JP, Evans D, Paulson JC, Wong CH, Ward AB, Wilson IA, Sanders RW, Poignard P, Burton DR. 2014. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity 40:657-668. http://dx.doi.org/10.1016/j.immuni.2014.04.009.
4. Huang JH, Kang BH, Pancera M, Lee JH, Tong T, Feng Y, Imamichi H, Georgiev IS, Chuang GY, Druz A, Doria-Rose NA, Laub L, Sliepen K, van Gils MJ, de la Pena AT, Derking R, Klasse PJ, Migueles SA, Bailer RT, Alam M, Pugach P, Haynes BF, Wyatt RT, Sanders RW, Binley JM, Ward AB, Mascola JR, Kwong PD, Connors M. 2014. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 515:138-142. http://dx.doi.org/10.1038/nature13601.
5. Kwong PD, Mascola JR. 2012. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 37:412-425. http://dx.doi.org/10.1016/j.immuni.2012.08.012.
6. Sok D, van Gils MJ, Pauthner M, Julien JP, Saye-Francisco KL, Hsueh J, Briney B, Lee JH, Le KM, Lee PS, Hua YZ, Seaman MS, Moore JP, Ward AB, Wilson IA, Sanders RW, Burton DR. 2014. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc Natl Acad SciUSA111:17624-17629. http://dx.doi.org/10.1073/pnas.1415789111.
7. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD, Koff WC, Wilson IA, Burton DR, Poignard P. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:466-470. http://dx.doi.org/10.1038/nature10373.
8. Wu XL, Yang ZY, Li YX, Hogerkorp CM, Schief WR, Seaman MS, Zhou TQ, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856-861. http://dx.doi.org/10.1126/science.1187659.
9. Zhou TQ, Georgiev I, Wu XL, Yang ZY, Dai KF, Finzi A, Kwon YD, Scheid JF, Shi W, Xu L, Yang YP, Zhu JA, Nussenzweig MC, Sodroski J, Shapiro L, Nabel GJ, Mascola JR, Kwong PD. 2010. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329:811-817. http://dx.doi.org/10.1126/science.1192819.
10. Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, Stephenson KE, Chang HW, Shekhar K, Gupta S, Nkolola JP, Seaman MS, Smith KM, Borducchi EN, Cabral C, Smith JY, Blackmore S, Sanisetty S, Perry JR, Beck M, Lewis MG, Rinaldi W, Chakraborty AK, Poignard P, Nussenzweig MC, Burton DR. 2013. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIVinfected rhesus monkeys. Nature 503:224-228. http://dx.doi.org/10.1038/nature12744.
11. Caskey M, Klein F, Lorenzi JCC, Seaman MS, West AP, Buckley N, Kremer G, Nogueira L, Braunschweig M, Scheid JF, Horwitz JA, Shimeliovich I, Ben-Avraham S, Witmer-Pack M, Platten M, Lehmann C, Burke LA, Hawthorne T, Gorelick RJ, Walker BD, Keler T, Gulick RM, Fatkenheuer G, Schlesinger SJ, Nussenzweig MC. 2015. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522:487-491. http://dx.doi.org/10.1038/nature14411.
12. Mascola JR. 2002. Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. Vaccine 20:1922-1925. http://dx.doi.org/10.1016/S0264-410X(02)00068-3.
13. Voronin Y, Mofenson LM, Cunningham CK, Fowler MG, Kaleebu P, McFarland EJ, Safrit JT, Graham BS, Snow W. 2014. HIV monoclonal antibodies: a new opportunity to further reduce mother-to-child HIV transmission. Plos Med 11:e1001616. http://dx.doi.org/10.1371/journal.pmed.1001616.
14. Huang JH, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, Imamichi H, Bailer RT, Chakrabarti B, Sharma SK, Alam SM, Wang T, Yang YP, Zhang BS, Migueles SA, Wyatt R, Haynes BF, Kwong PD, Mascola JR, Connors M. 2012. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491:406-412. http://dx.doi.org/10.1038/nature11544.
15. Lee JH, Ozorowski G, Ward AB. 2016. Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer. Science 351:1043-1048. http://dx.doi.org/10.1126/science.aad2450.
16. Cardoso RMF, Zwick MB, Stanfield RL, Kunert R, Binley JM, Katinger H, Burton DR, Wilson IA. 2005. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusionassociated motif in gp41. Immunity 22:163-173. http://dx.doi.org/10.1016/j.immuni.2004.12.011.
17. Zwick MB, Jensen R, Church S, Wang M, Stiegler G, Kunert R, Katinger H, Burton DR. 2005. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol 79:1252-1261. http://dx.doi.org/10.1128/JVI.79.2.1252-1261.2005.
18. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, Moore JP, Stiegler G, Katinger H, Burton DR, Parren PWHI. 2001. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75:10892-10905. http://dx.doi.org/10.1128/JVI.75.22.10892-10905.2001.
19. Kabsch W, Sander C. 1983. Dictionary of protein secondary structure-pattern-recognition of hydrogen-bonded and geometrical features. Biopolymers 22:2577-2637. http://dx.doi.org/10.1002/bip.360221211.
20. Gainza P, Roberts KE, Georgiev I, Lilien RH, Keedy DA, Chen CY, Reza F, Anderson AC, Richardson DC, Richardson JS, Donald BR. 2013. OSPREY: protein design with ensembles, flexibility, and provable algorithms. Methods Protein Design 523:87-107. http://dx.doi.org/10.1016/B978-0-12-394292-0.00005-9.
21. Sarzotti-Kelsoe M, Bailer RT, Turk E, Lin CL, Bilska M, Greene KM, Gao HM, Todd CA, Ozaki DA, Seaman MS, Mascola JR, Montefiori DC. 2014. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J Immunol Methods 409:131-146. http://dx.doi.org/10.1016/j.jim.2013.11.022.
22. Rudicell RS, Do Kwon Y, Ko SY, Pegu A, Louder MK, Georgiev IS, Wu XL, Zhu J, Boyington JC, Chen XJ, Shi W, Yang ZY, Doria-Rose NA, McKee K, O'Dell S, Schmidt SD, Chuang GY, Druz A, Soto C, Yang YP, Zhang BS, Zhou TQ, Todd JP, Lloyd KE, Eudailey J, Roberts KE, Donald BR, Bailer RT, Ledgerwood J, Mullikin JC, Shapiro L, Koup RA, Graham BS, Nason MC, Connors M, Haynes BF, Rao SS, Roederer M, Kwong PD, Mascola JR, Nabel GJ. 2014. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J Virol 88:12669-12682. http://dx.doi.org/10.1128/JVI.02213-14.
23. Majeed S, Ofek G, Belachew A, Huang CC, Zhou TQ, Kwong PD. 2003. Enhancing protein crystallization through precipitant synergy. Structure 11:1061-1070. http://dx.doi.org/10.1016/S0969-2126(03)00185-0.
24. Otwinowski Z, Minor W. 1997. Processing of X-ray diffraction data collected in oscillation mode. Macromol Crystallogr Part A 276:307-326. http://dx.doi.org/10.1016/S0076-6879(97)76066-X.
25. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. 2007. Phaser crystallographic software. J Appl Crystallogr 40: 658-674. http://dx.doi.org/10.1107/S0021889807021206.
26. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH. 2010. PHENIX: a comprehensive Pythonbased system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66:213-221. http://dx.doi.org/10.1107/S0907444909052925.
27. Emsley P, Cowtan K. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60:2126-2132. http://dx.doi.org/10.1107/S0907444904019158.
28. Cardoso RMF, Brunel FM, Ferguson S, Zwick M, Burton DR, Dawson PE, Wilson IA. 2007. Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10. J Mol Biol 365:1533-1544. http://dx.doi.org/10.1016/j.jmb.2006.10.088.
29. Chen J, Frey G, Peng H, Rits-Volloch S, Garrity J, Seaman MS, Chen B. 2014. Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41. J Virol 88:1249-1258. http://dx.doi.org/10.1128/JVI.02664-13.
30. Julien JP, Huarte N, Maeso R, Taneva SG, Cunningham A, Nieva JL, Pai EF. 2010. Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding. J Virol 84:4136-4147. http://dx.doi.org/10.1128/JVI.02357-09.
31. Kim M, Sun ZYJ, Rand KD, Shi XM, Song LK, Cheng YX, Fahmy AF, Majumdar S, Ofek G, Yang YP, Kwong PD, Wang JH, Engen JR, Wagner G, Reinherz EL. 2011. Antibody mechanics on a membranebound HIV segment essential for GP41-targeted viral neutralization. Nat Struct Mol Biol 18:1235-1243. http://dx.doi.org/10.1038/nsmb.2154.
32. Ofek G, McKee K, Yang YP, Yang ZY, Skinner J, Guenaga FJ, Wyatt R, Zwick MB, Nabel GJ, Mascola JR, Kwong PD. 2010. Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region. J Virol 84:2955-2962. http://dx.doi.org/10.1128/JVI.02257-09.
33. Ofek G, Tang M, Sambor A, Katinger H, Mascola JR, Wyatt R, Kwong PD. 2004. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 78:10724-10737. http://dx.doi.org/10.1128/JVI.78.19.10724-10737.2004.
34. Ofek G, Zirkle B, Yang YP, Zhu ZY, McKee K, Zhang BS, Chuang GY, Georgiev IS, O'Dell S, Doria-Rose N, Mascola JR, Dimitrov DS, Kwong PD. 2014. Structural basis for HIV-1 neutralization by 2F5-like antibodies m66 and m66.6. J Virol 88:2426-2441. http://dx.doi.org/10.1128/JVI.02837-13.
35. Sun ZYJ, Oh KJ, Kim MY, Yu J, Brusic V, Song LK, Qiao ZS, Wang JH, Wagner G, Reinherz EL. 2008. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity 28:52-63. http://dx.doi.org/10.1016/j.immuni.2007.11.018.
36. Georgiev IS, Rudicell RS, Saunders KO, Shi W, Kirys T, McKee K, O'Dell S, Chuang GY, Yang ZY, Ofek G, Connors M, Mascola JR, Nabel GJ, Kwong PD. 2014. Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline. J Immunol 192:1100-1106. http://dx.doi.org/10.4049/jimmunol.1302515.
37. Zhu J, Ofek G, Yang YP, Zhang BS, Louder MK, Lu G, McKee K, Pancera M, Skinner J, Zhang ZH, Parks R, Eudailey J, Lloyd KE, Blinn J, Alam SM, Haynes BF, Simek M, Burton DR, Koff WC, Mullikin JC, Mascola JR, Shapiro L, Kwong PD. 2013. Mining the antibodyome for HIV-1-neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains. Proc Natl Acad Sci U S A 110: 6470-6475. http://dx.doi.org/10.1073/pnas.1219320110.
38. Ko SY, Pegu A, Rudicell RS, Yang ZY, Joyce MG, Chen XJ, Wang KY, Bao S, Kraemer TD, Rath T, Zeng M, Schmidt SD, Todd JP, Penzak SR, Saunders KO, Nason MC, Haase AT, Rao SS, Blumberg RS, Mascola JR, Nabel GJ. 2014. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 514:642-645. http://dx.doi.org/10.1038/nature13612.
39. Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, Lazar GA, Roopenian DC, Desjarlais JR. 2010. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 28:157-159. http://dx.doi.org/10.1038/nbt.1601.
40. Pegu A, Yang ZY, Boyington JC, Wu L, Ko SY, Schmidt SD, McKee K, Kong WP, Shi W, Chen XJ, Todd JP, Letvin NL, Huang JH, Nason MC, Hoxie JA, Kwong PD, Connors M, Rao SS, Mascola JR, Nabel GJ. 2014. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med 6:243ra88. http://dx.doi.org/10.1126/scitranslmed.3008992.
41. Ledgerwood JE, Coates EE, Yamshchikov G, Saunders JG, Holman L, Enama ME, DeZure A, Lynch RM, Gordon I, Plummer S, Hendel CS, Pegu A, Conan-Cibotti M, Sitar S, Bailer RT, Narpala S, McDermott A, Louder M, O'Dell S, Mohan S, Pandey JP, Schwartz RM, Hu Z, Koup RA, Capparelli E, Mascola JR, Graham BS. 2015. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin Exp Immunol 182:289-301. http://dx.doi.org/10.1111/cei.12692.
42. Lynch RM, Boritz E, Coates EE, DeZure A, Madden P, Costner P, Enama ME, Plummer S, Holman L, Hendel CS, Gordon I, Casazza J, Conan-Cibotti M, Migueles SA, Tressler R, Bailer RT, McDermott A, Narpala S, O'Dell S, Wolf G, Lifson JD, Freemire BA, Gorelick RJ, Pandey JP, Mohan S, Chomont N, Fromentin R, Chun TW, Fauci AS, Schwartz RM, Koup RA, Douek DC, Hu Z, Capparelli E, Graham BS, Mascola JR, Ledgerwood JE. 2015. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med 7:319ra206. http://dx.doi.org/10.1126/scitranslmed.aad5752.
43. Meffre E, Catalan N, Seltz F, Fischer A, Nussenzweig MC, Durandy A. 2001. Somatic hypermutation shapes the antibody repertoire of memory B cells in humans. J Exp Med 194:375-378. http://dx.doi.org/10.1084/jem.194.3.375.
44. Wu XL, Zhang ZH, Schramm CA, Joyce MG, Do Kwon Y, Zhou TQ, Sheng ZZ, Zhang BS, O'Dell S, McKee K, Georgiev IS, Chuang GY, Longo NS, Lynch RM, Saunders KO, Soto C, Srivatsan S, Yang YP, Bailer RT, Louder MK, Mullikin JC, Connors M, Kwong PD, Mascola JR, Shapiro L. 2015. Maturation and diversity of the VRC01-antibody lineage over 15 years of chronic HIV-1 infection. Cell 161:470-485. http://dx.doi.org/10.1016/j.cell.2015.03.004.